Applications for Cell-Based Therapies and Biologics using Advanced High Throughput Flow Cytometry
23 September 2019 | 8:00 am PT | 11:00 am ET | 16:00 BST | 17:00 CEST
New immuno-oncology therapies that direct the immune system to identify and destroy cancer cells have revolutionized cancer treatment.
Antibodies can increase the engagement of immune and tumor cells stimulating killing, by direct cytotoxicity or phagocytosis.
Cell engineering approaches to create T and NK cells to seek and destroy cancer offer vast potential, with the first of these cell-based therapies receiving regulatory approval.
Therefore, a deeper understanding of immune/tumor cell interactions and processes leading to cancer cell eradication is critical to identify and validate new targets and therapeutic approaches.
In this webinar Dr John O’Rourke will:
- Illustrate the use of advanced high throughput flow cytometry to detect immune cell cytotoxicity with a variety of applications and model immunotherapeutics
- Discuss immune cell killing assays such as NK cell cytotoxicity
- Explain how to implement antibody dependent cytotoxicity and antibody dependent cellular phagocytosis assays
- Describe how advanced high throughput flow cytometry addresses bottlenecks in the development of biologics and cell-based therapies
Dr. John O’Rourke
Dr. John O’Rourke received his BS in chemistry from Northern Illinois University. He completed his PhD in Biochemistry from The Ohio State University where he studied cancer biology and gene regulation. During his postdoctoral training at Nationwide’s Children’s Research Institute and the University of New Mexico, he continued his studies in cancer biology and the development of viral and nanoparticle-based therapeutics. Dr. O’Rourke received his MBA from the Anderson School of Management at the University of New Mexico and joined Sartorius in 2017 as Manager of Assay Development. He is currently the Head of Product Development for Cell Analytics.